ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BLCM Bellicum Pharmaceuticals Inc

0.25
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Bellicum Pharmaceuticals Inc NASDAQ:BLCM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.25 0.20 0.50 0 01:00:00

(BLCM) Alert: Johnson Fistel, LLP Announces Investigation of Bellicum Pharmaceuticals, Inc.; Long Term Investors Encouraged t...

20/05/2019 1:38pm

PR Newswire (US)


Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Bellicum Pharmaceuticals Charts.

SAN DIEGO, May 20, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) ("Bellicum")  and certain of its officers.

Last year a securities class action lawsuit was filed on behalf of purchasers of the securities of Bellicum from May 8, 2017 and January 30, 2018, (the "Class Period"). According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) a substantial undisclosed risk of encephalopathy was associated with the Bellicum's lead product candidate, BPX-501; and (2) as a result, Bellicum's public statements were materially false and misleading at all relevant times.

If you are a long-term shareholder of Bellicum continuously holding shares before May 8, 2017, you may have standing to hold Bellicum harmless from the alleged harm caused by the officers and directors of the Company by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.

If you are interested in learning more about your legal rights and remedies, please contact Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If you email, please include your phone number.

Additionally, you can  [click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com

[click here to join this action]

Cision View original content:http://www.prnewswire.com/news-releases/blcm-alert-johnson-fistel-llp-announces-investigation-of-bellicum-pharmaceuticals-inc-long-term-investors-encouraged-to-contact-firm-300853100.html

SOURCE Johnson Fistel, LLP

Copyright 2019 PR Newswire

1 Year Bellicum Pharmaceuticals Chart

1 Year Bellicum Pharmaceuticals Chart

1 Month Bellicum Pharmaceuticals Chart

1 Month Bellicum Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock